1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinibJ. De Langen, Helena A. Yu, Zofia Piotrowska et al.|Annals of Oncology|2022Cited by 7